Cetera Investment Advisers increased its position in shares of GlaxoSmithKline PLC (NYSE:GSK) by 7.6% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 25,975 shares of the pharmaceutical company’s stock after buying an additional 1,836 shares during the period. Cetera Investment Advisers’ holdings in GlaxoSmithKline PLC were worth $1,115,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Nelson Van Denburg & Campbell Wealth Management Group LLC raised its stake in GlaxoSmithKline PLC by 1,747.4% during the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 2,494 shares of the pharmaceutical company’s stock worth $105,000 after buying an additional 2,359 shares during the last quarter. Proficio Capital Partners LLC raised its stake in GlaxoSmithKline PLC by 233.0% during the first quarter. Proficio Capital Partners LLC now owns 2,844 shares of the pharmaceutical company’s stock worth $122,000 after buying an additional 1,990 shares during the last quarter. Westwood Holdings Group Inc. raised its stake in GlaxoSmithKline PLC by 15.7% during the first quarter. Westwood Holdings Group Inc. now owns 2,950 shares of the pharmaceutical company’s stock worth $124,000 after buying an additional 400 shares during the last quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA raised its stake in GlaxoSmithKline PLC by 1.9% during the second quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 3,374 shares of the pharmaceutical company’s stock worth $137,000 after buying an additional 64 shares during the last quarter. Finally, FTB Advisors Inc. raised its stake in GlaxoSmithKline PLC by 16.9% during the second quarter. FTB Advisors Inc. now owns 3,735 shares of the pharmaceutical company’s stock worth $146,000 after buying an additional 539 shares during the last quarter. 9.28% of the stock is owned by institutional investors and hedge funds.

GlaxoSmithKline PLC (GSK) traded down 0.10% during midday trading on Monday, hitting $40.97. 1,621,494 shares of the stock traded hands. The stock’s 50-day moving average price is $40.35 and its 200-day moving average price is $41.57. GlaxoSmithKline PLC has a 52 week low of $37.20 and a 52 week high of $44.54. The stock has a market capitalization of $100.13 billion, a P/E ratio of 39.70 and a beta of 1.03.

GlaxoSmithKline PLC (NYSE:GSK) last issued its quarterly earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.70 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.68 by $0.02. The company had revenue of $9.36 billion during the quarter, compared to analyst estimates of $9.52 billion. GlaxoSmithKline PLC had a net margin of 6.48% and a return on equity of 114.93%. Equities research analysts expect that GlaxoSmithKline PLC will post $2.87 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Thursday, October 12th. Investors of record on Friday, August 11th were paid a $0.491 dividend. This represents a $1.96 annualized dividend and a dividend yield of 4.79%. This is a positive change from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. The ex-dividend date was Wednesday, August 9th. GlaxoSmithKline PLC’s dividend payout ratio (DPR) is presently 198.00%.

ILLEGAL ACTIVITY WARNING: This report was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.watchlistnews.com/cetera-investment-advisers-has-1-12-million-position-in-glaxosmithkline-plc-gsk/1634763.html.

A number of equities analysts recently weighed in on the stock. J P Morgan Chase & Co reissued a “neutral” rating on shares of GlaxoSmithKline PLC in a research note on Thursday, September 21st. Citigroup Inc. downgraded shares of GlaxoSmithKline PLC from a “buy” rating to a “neutral” rating in a research note on Wednesday, July 5th. BidaskClub downgraded shares of GlaxoSmithKline PLC from a “sell” rating to a “strong sell” rating in a research note on Monday, July 24th. TheStreet downgraded shares of GlaxoSmithKline PLC from a “b” rating to a “c+” rating in a research note on Wednesday, July 26th. Finally, Zacks Investment Research downgraded shares of GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a research note on Friday, July 21st. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and seven have assigned a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $44.67.

GlaxoSmithKline PLC Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Institutional Ownership by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.